Business Context and Reporting Period
Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc.) filed a Form 8-K on November 19, 2025. The company is a Delaware corporation with its principal executive office in Cambridge, MA, and its common stock trades on The Nasdaq Capital Market under the symbol "CYPH". The filing reports the entry into a material definitive agreement regarding warrant modifications.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on a corporate action involving equity instruments.
Material Changes and Agreements
On November 19, 2025, the Company entered into a Waiver and Modification Agreement with Winklevoss Treasury Investments, LLC ("Winklevoss Capital"). Key terms include:
- Waiver of Share Reservation: Winklevoss Capital waived the Share Reservation Covenant for 57,182,378 Warrant Shares ("Restricted Warrant Shares").
- ATM Program Availability: The waiver makes the Restricted Warrant Shares available for the Company's "at-the-market" (ATM) equity offering program, which allows for the sale of up to $200 million of common stock.
- Exercise Restrictions: Winklevoss Capital cannot exercise the WTI Common Warrant for the Restricted Warrant Shares until the fifth trading day after the earlier of:
- The Company's authorized common stock increases to at least 490,000,000 shares; or
- The Company effects a reverse stock split of at least 1:5.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general business risks. The primary contingency noted is the restriction on the exercise of the WTI Common Warrant until specific capital structure thresholds are met.
Investor Verification Checklist
- Verify the current number of authorized common shares to determine if the 490,000,000 share threshold for warrant exercise has been met.
- Confirm the status of the Company's $200 million "at-the-market" equity offering program.
- Review the full text of the Waiver and Modification Agreement (Exhibit 4.1) for additional covenants not summarized in the 8-K.
- Monitor for any announcements regarding a potential reverse stock split.